Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
Rani Therapeutics (Nasdaq: RANI) will report fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026 after market close. Management will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT.
Investors can access the live webcast and a replay via the company’s investor relations website at www.ranitherapeutics.com.
Positive
- None.
Negative
- None.
News Market Reaction – RANI
In the Mar 20 session, RANI declined 1.74%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 28 | Leadership promotion | Positive | -2.9% | Promotion of Alireza Javadi, Ph.D., to Chief Technical Officer. |
| Jan 08 | Phase 1 trial start | Positive | +0.0% | Initiation of Phase 1 study of RT-114 RaniPill for obesity. |
| Nov 24 | Conference participation | Positive | -3.0% | Announcement of participation in the Evercore Healthcare Conference. |
| Nov 06 | Earnings and update | Positive | -11.0% | Q3 2025 financial results and Chugai collaboration plus financing update. |
| Oct 30 | Preclinical data | Positive | -12.7% | Preclinical data on oral semaglutide via RaniPill at ObesityWeek 2025. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news, including partnerships, clinical updates, conferences, and earnings, has often coincided with flat to negative price reactions, indicating a pattern where announcements have not translated into sustained upside.
Over the last few months, Rani issued several updates, including preclinical and clinical advances for obesity and oral semaglutide, governance and financing actions tied to private placements, and a major Chugai collaboration potentially worth $1.085 billion. Yet prior earnings and conference announcements on Nov 6, 2025 and Nov 24, 2025 were followed by double‑digit and mid‑single‑digit declines. The upcoming Q4 and full‑year 2025 results follow this backdrop of scientific progress but muted or negative share responses.
Key Terms
biologics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2025 and provide a business update on Thursday, March 26, 2026 after the close of trading. Rani’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.
Conference Call and Webcast
Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 26, 2026. Individuals interested in listening to the live conference call may do so by using the webcast link in the “Investors” section of the company’s website at www.ranitherapeutics.com. A webcast replay will be available in the investor relations section on the company’s website following the completion of the call.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
media@ranitherapeutics.com
